Taysha Gene Therapies’ (TSHA) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research note published on Thursday,Benzinga reports. The brokerage currently has a $6.00 price target on the stock.

Separately, Chardan Capital reiterated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies presently has an average rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $1.25 on Thursday. The firm has a market cap of $255.23 million, a PE ratio of 1.98 and a beta of 0.96. Taysha Gene Therapies has a 12 month low of $1.05 and a 12 month high of $4.32. The company’s fifty day simple moving average is $1.58 and its 200-day simple moving average is $1.84. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The business had revenue of $2.02 million during the quarter, compared to analysts’ expectations of $2.05 million. Equities research analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Taysha Gene Therapies

Large investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its position in Taysha Gene Therapies by 7.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock valued at $930,000 after buying an additional 33,123 shares in the last quarter. State Street Corp grew its stake in Taysha Gene Therapies by 4.5% in the third quarter. State Street Corp now owns 3,469,068 shares of the company’s stock valued at $6,973,000 after acquiring an additional 150,647 shares during the period. Wellington Management Group LLP bought a new stake in shares of Taysha Gene Therapies during the third quarter valued at approximately $931,000. Barclays PLC raised its position in shares of Taysha Gene Therapies by 356.0% during the third quarter. Barclays PLC now owns 247,280 shares of the company’s stock worth $513,000 after purchasing an additional 193,046 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Taysha Gene Therapies by 23.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after purchasing an additional 682,273 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.